compounding semaglutide fda alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA proposes curbs on mass

NIH had a $48 billion taxpayer-funded 1 year, 2025 budget yet ZERO clinical trials

What Regulators Say After extensive review, regulatory agencies have concluded: No confirmed causal link between GLP-1 medications and anger or aggression No black box warnings related to mood Continued monitoring is appropriate This reflects a balanced interpretation of available evidencenot dismissal of patient experiences, but also not overstating risk

Treatment decisions should consider medical history, side effects, medication access, and provider recommendations

What if my insurance requires a higher BMI than the FDA threshold

But along with their high cost and troubling side effects, obesity drugs have another downside: Roughly half the people who start on the drugs stop taking what is meant to be lifetime medication within a year of starting